Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings

Core Insights - Abbott reported revenue of $10.64 billion for the quarter ended September 2024, reflecting a year-over-year increase of 4.9% and an EPS of $1.21, up from $1.14 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $10.56 billion by 0.71%, while the EPS also surpassed the consensus estimate of $1.20 by 0.83% [1] Financial Performance Metrics - Nutrition - U.S.: Net sales of $950 million, exceeding the average estimate of $918.13 million, with a year-over-year increase of 10.5% [2] - Nutrition - International: Net sales of $1.12 billion, below the average estimate of $1.26 billion, representing a year-over-year decline of 8% [2] - Diagnostics - International: Net sales of $1.38 billion, slightly below the average estimate of $1.39 billion, with a year-over-year decrease of 3.9% [2] - Diagnostics - U.S.: Net sales of $1.03 billion, surpassing the average estimate of $919.77 million, reflecting a year-over-year increase of 1.9% [2] - Diagnostics Total: Net sales of $2.41 billion, exceeding the average estimate of $2.31 billion, with a year-over-year decline of 1.5% [2] - Medical Devices - Diabetes Care: Net sales of $1.73 billion, slightly above the average estimate of $1.72 billion, with a year-over-year increase of 17.2% [2] - Nutrition Total: Net sales of $2.07 billion, below the average estimate of $2.17 billion, representing a year-over-year decline of 0.3% [2] - Medical Devices - Rhythm Management: Net sales of $597 million, slightly above the average estimate of $595.52 million, with a year-over-year increase of 6% [2] - Medical Devices Total: Net sales of $4.75 billion, exceeding the average estimate of $4.70 billion, with a year-over-year increase of 11.7% [2] - Medical Devices - Neuromodulation: Net sales of $236 million, below the average estimate of $242.90 million, with a year-over-year increase of 4% [2] - Established Pharmaceuticals: Net sales of $1.41 billion, matching the average estimate, with a year-over-year increase of 2.8% [2] - Medical Devices - Vascular: Net sales of $699 million, slightly above the average estimate of $695.35 million, with a year-over-year increase of 4% [2] Stock Performance - Abbott's shares have returned -1.8% over the past month, while the Zacks S&P 500 composite has increased by 3.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]